Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN20423 in Healthy Participants and Atopic Dermatitis
NCT07527923Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of REGN20423 in atopic dermatitis (AD) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment Emergent Adverse Events at 69 weeks and Severity of Treatment Emergent Adverse Events at 69 weeks. Started May 2026; status: recruiting.
02
Drugs
REGN20423
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07527923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527923.